Last reviewed · How we verify
Exenatide and Dapagliflozin
At a glance
| Generic name | Exenatide and Dapagliflozin |
|---|---|
| Also known as | Byetta plus Dapagliflozin |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes (NA)
- Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria (PHASE4)
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: